Literature DB >> 10096544

Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.

M Murakami1, K J Gurski, F M Marincola, J Ackland, M A Steller.   

Abstract

When intracellular viral proteins are degraded, only a limited number of peptide epitopes are capable of eliciting specific CD8+ cellular immune responses for a given human leukocyte antigen (HLA) haplotype. We sought to induce CD8+ T-lymphocyte (CTL) responses to human papillomavirus-16 (HPV-16) E6 and E7 proteins using a recombinant E6/E7 fusion protein and autologous human dendritic cells (DCs). CTLs were generated by in vitro stimulation using a recombinant HPV-16 E6/E7 fusion protein and autologous DCs from a healthy HLA-A*0201 donor. CTL specificity was assessed by cytokine release assays when the cells were reacted with autologous DC targets coincubated with the E6/E7 fusion protein. These CTLs were also reacted with the immunodominant E7 peptides (E711-20 and E7(86-93)) and DCs as a target. As a negative control, DCs were incubated with or without an irrelevant control protein (Helicobacter pylori) as target for the E6/E7-induced CTLs. The E6/E7-induced CTLs were capable of specific recognition of target DCs coincubated with E6/E7 but not the control protein. When E6/E7-specific CTLs were reacted with DCs and either E7(11-20) or E7(86-93), specific peptide recognition was also detected. These data demonstrate that specific CTLs can be elicited using autologous human DCs and a HPV-16 E6/E7 fusion protein. Therefore, extracellular viral proteins seem to be engulfed and processed by DCs; then the immunodominant HLA-A2-restricted peptides become available for CD8+ T-lymphocyte recognition. These data suggest that vaccine strategies using recombinant viral proteins may overcome the limitation of peptide epitopes for specific HLA haplotypes and may, therefore, permit more generalized clinical application.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096544

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Current state in the development of candidate therapeutic HPV vaccines.

Authors:  Andrew Yang; Jessica Jeang; Kevin Cheng; Ting Cheng; Benjamin Yang; T-C Wu; Chien-Fu Hung
Journal:  Expert Rev Vaccines       Date:  2016-03-07       Impact factor: 5.217

2.  Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.

Authors:  Mi Suk Kim; Jeong-Im Sin
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

Review 3.  Immunotherapy for cervical cancer: Research status and clinical potential.

Authors:  Jun-Han Su; Anjui Wu; Elizabeth Scotney; Barbara Ma; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  BioDrugs       Date:  2010-04-01       Impact factor: 5.807

4.  Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.

Authors:  H Höhn; H Pilch; S Günzel; C Neukirch; K Freitag; A Necker; M J Maeurer
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 5.  Perspectives for preventive and therapeutic HPV vaccines.

Authors:  Ken Lin; Kimberley Doolan; Chien-Fu Hung; T C Wu
Journal:  J Formos Med Assoc       Date:  2010-01       Impact factor: 3.282

6.  CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.

Authors:  Tai-Gyu Kim; Chang-Hyun Kim; Eun Ha Won; Su Mi Bae; Woong-Shick Ahn; Jae-Bok Park; Jeong-Im Sin
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

Review 7.  The current state of therapeutic and T cell-based vaccines against human papillomaviruses.

Authors:  Andrew Yang; Emily Farmer; John Lin; T-C Wu; Chien-Fu Hung
Journal:  Virus Res       Date:  2016-12-06       Impact factor: 3.303

Review 8.  Therapeutic HPV DNA vaccines.

Authors:  Archana Monie; Shaw-Wei D Tsen; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

9.  Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.

Authors:  Marion Nonn; Manuela Schinz; Klaus Zumbach; Michael Pawlita; Achim Schneider; Matthias Dürst; Andreas M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-02       Impact factor: 4.553

Review 10.  Cervical Cancer Immunotherapy: Facts and Hopes.

Authors:  Louise Ferrall; Ken Y Lin; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Clin Cancer Res       Date:  2021-04-22       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.